Kumar K, Madhusoodanan M, Pangath M, Menon D
Drug Deliv Transl Res. 2025; .
PMID: 39888579
DOI: 10.1007/s13346-024-01765-w.
Graciotti M, Kandalaft L
Nat Rev Drug Discov. 2024; 24(2):134-150.
PMID: 39622986
DOI: 10.1038/s41573-024-01081-5.
Zhou R, Wu S, Yazdanifar M, Williams C, Sanders A, Brouwer C
J Immunother. 2024; 47(3):77-88.
PMID: 38270462
PMC: 10913860.
DOI: 10.1097/CJI.0000000000000505.
Blazeska N, Kosaloglu-Yalcin Z, Vita R, Peters B, Sette A
Methods Mol Biol. 2023; 2673:133-149.
PMID: 37258911
PMC: 11008223.
DOI: 10.1007/978-1-0716-3239-0_9.
Murwanti R, Denda-Nagai K, Sugiura D, Mogushi K, Gendler S, Irimura T
Cancers (Basel). 2023; 15(6).
PMID: 36980805
PMC: 10047104.
DOI: 10.3390/cancers15061920.
Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma.
Schoen R, Boardman L, Cruz-Correa M, Bansal A, Kastenberg D, Hur C
Clin Cancer Res. 2023; 29(9):1678-1688.
PMID: 36892581
PMC: 10159922.
DOI: 10.1158/1078-0432.CCR-22-3168.
Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches.
Emran T, Shahriar A, Mahmud A, Rahman T, Abir M, Siddiquee M
Front Oncol. 2022; 12:891652.
PMID: 35814435
PMC: 9262248.
DOI: 10.3389/fonc.2022.891652.
LCVM infection generates tumor antigen-specific immunity and inhibits growth of nonviral tumors.
Jacqueline C, Dracz M, Xue J, Binder R, Minden J, Finn O
Oncoimmunology. 2022; 11(1):2029083.
PMID: 35083098
PMC: 8786340.
DOI: 10.1080/2162402X.2022.2029083.
T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins.
Xu Y, Salazar G, Zhang N, An Z
Antib Ther. 2021; 2(1):22-32.
PMID: 33928218
PMC: 7990144.
DOI: 10.1093/abt/tbz001.
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion.
Jhunjhunwala S, Hammer C, Delamarre L
Nat Rev Cancer. 2021; 21(5):298-312.
PMID: 33750922
DOI: 10.1038/s41568-021-00339-z.
Immunotherapy Advances for Epithelial Ovarian Cancer.
Hartnett E, Knight J, Radolec M, Buckanovich R, Edwards R, Vlad A
Cancers (Basel). 2020; 12(12).
PMID: 33322601
PMC: 7764119.
DOI: 10.3390/cancers12123733.
An Overview of Cancer Prevention: Chemoprevention and Immunoprevention.
Gu K, Li G
J Cancer Prev. 2020; 25(3):127-135.
PMID: 33033707
PMC: 7523034.
DOI: 10.15430/JCP.2020.25.3.127.
Inflammation-Induced Abnormal Expression of Self-molecules on Epithelial Cells: Targets for Tumor Immunoprevention.
Jacqueline C, Lee A, Frey N, Minden J, Finn O
Cancer Immunol Res. 2020; 8(8):1027-1038.
PMID: 32467324
PMC: 7415557.
DOI: 10.1158/2326-6066.CIR-19-0870.
Mass spectrometry for the identification and analysis of highly complex glycosylation of therapeutic or pathogenic proteins.
Ohyama Y, Nakajima K, Renfrow M, Novak J, Takahashi K
Expert Rev Proteomics. 2020; 17(4):275-296.
PMID: 32406805
PMC: 7372739.
DOI: 10.1080/14789450.2020.1769479.
Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention.
Jacqueline C, Finn O
Semin Immunol. 2020; 47:101394.
PMID: 32273212
PMC: 7164634.
DOI: 10.1016/j.smim.2020.101394.
Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?.
Dhodapkar M, Dhodapkar K
Front Immunol. 2019; 10:2385.
PMID: 31649683
PMC: 6795703.
DOI: 10.3389/fimmu.2019.02385.
Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses.
Quandt J, Schlude C, Bartoschek M, Will R, Cid-Arregui A, Scholch S
Oncoimmunology. 2018; 7(12):e1500671.
PMID: 30524892
PMC: 6279329.
DOI: 10.1080/2162402X.2018.1500671.
Expression of mucin-1 in oral squamous cell carcinoma and normal oral mucosa: An immunohistochemical study.
Thakur A, Tupkari J, Joy T, Kende P, Siwach P, Ahire M
J Oral Maxillofac Pathol. 2018; 22(2):210-215.
PMID: 30158774
PMC: 6097386.
DOI: 10.4103/jomfp.JOMFP_188_17.
Cancer immunoprevention: from mice to early clinical trials.
Palladini A, Landuzzi L, Lollini P, Nanni P
BMC Immunol. 2018; 19(1):16.
PMID: 29902992
PMC: 6003025.
DOI: 10.1186/s12865-018-0253-0.
Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.
Jindal V, Arora E, Gupta S, Lal A, Masab M, Potdar R
Med Oncol. 2018; 35(5):70.
PMID: 29651744
DOI: 10.1007/s12032-018-1131-6.
